This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy and Acceptability of Two Lubricant Eye Drops

This study has been completed.
Information provided by (Responsible Party):
Allergan Identifier:
First received: September 18, 2008
Last updated: September 22, 2011
Last verified: September 2011
Efficacy and acceptability of two new artificial tears following two weeks of treatment in patients with dry eye. Patients will be randomized to 1 of 2 treatments for 7 days then crossover to the alternate treatment for 7 days.

Condition Intervention Phase
Dry Eye Syndromes Drug: Lubricant Eye Drops (Optive™) Drug: Lubricating Eye Drops (blink® Tears) Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Allergan:

Primary Outcome Measures:
  • Mean Frequency of Eye Drop Use Over 1 Week [ Time Frame: 1 week ]
    Mean frequency of eye drop use per day per patient during the cross-over period over 1 week. Eye drop use was captured on a daily tear diary that the patients completed. The greater the frequency of use, the more eye drops were required to manage the patient's dry eye symptoms.

Secondary Outcome Measures:
  • Change From Baseline in Dry Eye Disease Comfort Assessment Score on Day 16 [ Time Frame: Baseline, Day 16 ]
    Mean change from baseline in Dry Eye Disease Comfort Assessment Score at Day 16. The Dry Eye Disease Comfort Assessment consists of one question asking the patient to rate their current overall discomfort from their dry eye symptoms on a scale of 0 to 10 (0 equals No Discomfort; 10 equals Intolerable). The greater the negative number change from baseline, the greater the improvement in comfort.

  • Percentage of Positive Patient Responses to Subject Acceptability Questionnaire on Day 16 [ Time Frame: Day 16 ]
    Percentage of patients who responded "Strongly Agree" and "Agree" to Subject Acceptability Questionnaire Question 1: Overall Liked. The Subject Acceptability Questionnaire consists of 11 multiple choice questions assessing how the patients feel about the eye drops received. The 5 possible responses to the questionnaire are "Strongly Agree", "Agree", "Neither Agree or Disagree", "Disagree" and "Strongly Disagree".

  • Number of Patients With Positive Responses to Subject Preference Questionnaire on Day 16 [ Time Frame: Day 16 ]
    Number of patients who marked that either Week 1 study product was more soothing or Week 2 study product was more soothing to the Overall Comfort Preference Questionnaire on Day 16 of the cross-over period. The Subject Preference Questionnaire consists of 4 questions related to comfort, soothing, blurring and purchase preference comparing treatments received during Week 1 versus Week 2.

Enrollment: 51
Study Start Date: September 2008
Study Completion Date: August 2009
Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Carboxymethylcellulose and Glycerin
Drug: Lubricant Eye Drops (Optive™)
1 drop in both eyes as needed for 7 days`
Other Name: Optive™
Active Comparator: 2
Polyethylene glycol 400
Drug: Lubricating Eye Drops (blink® Tears)
1 drop in both eyes as needed for 7 days
Other Name: blink® Tears


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Male or Female
  • At least 18 years of age
  • Current use of artificial tears

Exclusion Criteria:

  • Any uncontrolled systemic disease
  • Pregnancy or planning a pregnancy
  • Contact lens wear
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00756678

United States, Maryland
Chevy Chase, Maryland, United States
Sponsors and Collaborators
Study Director: Medical Director Allergan
  More Information

Responsible Party: Allergan Identifier: NCT00756678     History of Changes
Other Study ID Numbers: MA-OPT-08-001
Study First Received: September 18, 2008
Results First Received: September 22, 2011
Last Updated: September 22, 2011

Additional relevant MeSH terms:
Dry Eye Syndromes
Keratoconjunctivitis Sicca
Lacrimal Apparatus Diseases
Eye Diseases
Conjunctival Diseases
Corneal Diseases
Ophthalmic Solutions
Lubricant Eye Drops
Pharmaceutical Solutions
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Nasal Decongestants
Vasoconstrictor Agents
Respiratory System Agents processed this record on July 27, 2017